Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA
Cristina Rubín de Célix, Elena Ricart, María Dolores Martín‐Arranz, Ruth de Francisco et autres
BACKGROUND: Real-world data on dose escalation/de-escalation in inflammatory bowel disease (IBD) are scarce. AIMS: To assess the frequency, effectiveness and durability of escalation/de-escalation of infliximab, adalimumab, golimumab, vedolizumab and ustekinumab in IBD, and to identify factors influencing relapse and drug discontinuation and …
es, mx, us (code pays fourni par la source)
7 citations
Alimentary Pharmacology & Therapeutics